{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:19:06Z","timestamp":1790245146674,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.autrev.2014.10.017","type":"journal-article","created":{"date-parts":[[2014,10,16]],"date-time":"2014-10-16T02:54:34Z","timestamp":1413428074000},"page":"168-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study"],"prefix":"10.1016","volume":"14","author":[{"given":"Guillaume","family":"Moulis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Sailler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2014.10.017_bb0005","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.autrev.2014.01.026","article-title":"Diagnosis and classification of immune-mediated thrombocytopenia","volume":"13","author":"Lo","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.10.017_bb0010","doi-asserted-by":"crossref","first-page":"A342","DOI":"10.1016\/j.autrev.2009.11.020","article-title":"The geoepidemiology of immune thrombocytopenic purpura","volume":"9","author":"Deane","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.10.017_bb0015","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.10.017_bb0020","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.10.017_bb0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V88.1.3.3","article-title":"Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology","volume":"88","author":"George","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.10.017_bb0030","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.10.017_bb0035","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2515\/therapie\/2014056","article-title":"Pharmacoepidemiology of immune thrombocytopenia: protocols of FAITH and CARMEN studies","volume":"69","author":"Moulis","year":"2014","journal-title":"Therapie"},{"key":"10.1016\/j.autrev.2014.10.017_bb0040","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.respe.2010.04.005","article-title":"French national health insurance information system and the permanent beneficiaries sample","volume":"58","author":"Tuppin","year":"2010","journal-title":"Rev Epidemiol Sante Publique"},{"key":"10.1016\/j.autrev.2014.10.017_bb0045","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2014-05-578336","article-title":"Epidemiology of incident immune thrombocytopenia in France: a nationwide population-based study","author":"Moulis","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.10.017_bb0050","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.autrev.2014.10.017_bb0055","article-title":"Score de Charlson \u00e0 partir des donn\u00e9es du Sniiram cha\u00een\u00e9es au PMSI: faisabilit\u00e9 et valeur pronostique sur la mortalit\u00e9 \u00e0 un an","volume":"S9","author":"Bannay","year":"2013","journal-title":"Rev Epidemiol Sante Publique"},{"key":"10.1016\/j.autrev.2014.10.017_bb0060","first-page":"829","article-title":"Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count","volume":"90","author":"Khellaf","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.autrev.2014.10.017_bb0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ajh.23580","article-title":"Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity","volume":"89","author":"Moulis","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2014.10.017_bb0070","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1182\/blood-2011-12-309153","article-title":"How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment","volume":"120","author":"Ghanima","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.10.017_bb0075","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/blood.V122.21.450.450","article-title":"Safety and efficacy of rituximab in adult's immune thrombocytopenia (ITP): results after one-year of follow-up in 252 patients from the Prospective French ITP-Ritux Registry","volume":"122","author":"Khellaf","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.10.017_bb0080","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.amjmed.2003.12.024","article-title":"Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results","volume":"116","author":"Maloisel","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2014.10.017_bb0085","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1046\/j.1365-2141.1997.412687.x","article-title":"Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases","volume":"97","author":"Godeau","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2014.10.017_bb0090","author":"Haute Autorit\u00e9 de Sant\u00e9"},{"key":"10.1016\/j.autrev.2014.10.017_bb0095","first-page":"75","article-title":"Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases","volume":"29","author":"Arnal","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2014.10.017_bb0100","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ajh.23609","article-title":"Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies","volume":"89","author":"Khellaf","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2014.10.017_bb0105","doi-asserted-by":"crossref","first-page":"298369","DOI":"10.1155\/2012\/298369","article-title":"Estimation of national colorectal-cancer incidence using claims databases","volume":"2012","author":"Quantin","year":"2012","journal-title":"J Cancer Epidemiol"},{"key":"10.1016\/j.autrev.2014.10.017_bb0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2014.10.017_bb0115","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.autrev.2014.08.036","article-title":"Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature","volume":"13","author":"Levy","year":"2014","journal-title":"Autoimmun Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214002389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214002389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T21:24:28Z","timestamp":1598390668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997214002389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S1568997214002389"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2014.10.017","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2014.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}